<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02513732</url>
  </required_header>
  <id_info>
    <org_study_id>14-306</org_study_id>
    <nct_id>NCT02513732</nct_id>
  </id_info>
  <brief_title>XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)</brief_title>
  <official_title>XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of XIENCE Xpedition
      Everolimus-Eluting 2.25mm Stent in real world practice in Japanese hospitals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on Good Post-marketing Study Practice (GPSP) regulation, general patient population
      with ischemic heart disease who are eligible for treatment with XIENCE Xpedition
      Everolimus-Eluting 2.25mm Stent will be registered, with no particular inclusion/exclusion
      criteria, and may be eligible for angiographic follow-up at eight months and clinical
      follow-up at one year.

      The XIENCE Xpedition 2.25 mm stent is composed of the stent identical to the stent of the
      XIENCE PRIME SV Stent.Therefore, the data collected from the PMS will be pooled with data
      collected from the ongoing XIENCE PRIME SV PMS for analysis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stent Thrombosis: acute</measure>
    <time_frame>0-24 hours post stent implantation</time_frame>
    <description>Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent Thrombosis: subacute</measure>
    <time_frame>&gt;24 hours to 30 days post stent implantation</time_frame>
    <description>Definite + Probable Stent Thrombosis Rate Based on ARC definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent Thrombosis: late</measure>
    <time_frame>30 days to 1 year post stent implantation</time_frame>
    <description>Definite + Probable Stent Thrombosis Rate Based on ARC definition. Definite + Probable Stent Thrombosis Rate Based on ARC definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent thrombosis: very late</measure>
    <time_frame>&gt;1 year post stent implantation</time_frame>
    <description>Definite + Probable Stent Thrombosis Rate Based on ARC definition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>At baseline before procedure</time_frame>
    <description>In-segment, In-stent, Proximal and Distal. The value calculated as 100 * (1 - minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>Participants will be followed post procedure through discharge, an expected duration of 1 week</time_frame>
    <description>In-segment, In-stent, Proximal and Distal. The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>8 months</time_frame>
    <description>In-segment, In-stent, Proximal and Distal. The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis In Myocardial Infarction (TIMI) Flow</measure>
    <time_frame>At baseline before procedure</time_frame>
    <description>Grade 0: No contrast flow through the stenosis; Grade 1: A small amount of contrast flows through the stenosis but fails to fully opacify the artery beyond; Grade 2: Contrast material flows through the stenosis to opacify the terminal artery segment. However, contrast enters the terminal segment perceptibly more slowly than more proximal segments. Alternatively, contrast material clears from a segment distal to a stenosis noticeably more slowly than from a comparable segment not preceded by a significant stenosis; Grade 3: Anterograde flow into the terminal coronary artery segment through a stenosis is as prompt as anterograde flow into a comparable segment proximal to the stenosis. Contrast material clears as rapidly from the distal segment as from an uninvolved, more proximal segment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis In Myocardial Infarction (TIMI) Flow</measure>
    <time_frame>Participants will be followed post procedure through discharge, an expected duration of 1 week</time_frame>
    <description>Grade 0: No contrast flow through the stenosis; Grade 1: A small amount of contrast flows through the stenosis but fails to fully opacify the artery beyond; Grade 2: Contrast material flows through the stenosis to opacify the terminal artery segment. However, contrast enters the terminal segment perceptibly more slowly than more proximal segments. Alternatively, contrast material clears from a segment distal to a stenosis noticeably more slowly than from a comparable segment not preceded by a significant stenosis; Grade 3: Anterograde flow into the terminal coronary artery segment through a stenosis is as prompt as anterograde flow into a comparable segment proximal to the stenosis. Contrast material clears as rapidly from the distal segment as from an uninvolved, more proximal segment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis In Myocardial Infarction (TIMI) Flow</measure>
    <time_frame>8 months</time_frame>
    <description>Grade 0: No contrast flow through the stenosis; Grade 1: A small amount of contrast flows through the stenosis but fails to fully opacify the artery beyond; Grade 2: Contrast material flows through the stenosis to opacify the terminal artery segment. However, contrast enters the terminal segment perceptibly more slowly than more proximal segments. Alternatively, contrast material clears from a segment distal to a stenosis noticeably more slowly than from a comparable segment not preceded by a significant stenosis; Grade 3: Anterograde flow into the terminal coronary artery segment through a stenosis is as prompt as anterograde flow into a comparable segment proximal to the stenosis. Contrast material clears as rapidly from the distal segment as from an uninvolved, more proximal segment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants using antiplatelet therapy</measure>
    <time_frame>At baseline before procedure</time_frame>
    <description>Percentage of patients using aspirin, clopidogrel, ticlopidine, cilostazol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants using maintenance antiplatelet therapy</measure>
    <time_frame>Participants will be followed post procedure through discharge, an expected duration of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants changing or terminating antiplatelet therapy</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants changing or terminating antiplatelet therapy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants changing or terminating antiplatelet therapy</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants changing or terminating antiplatelet therapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants changing or terminating antiplatelet therapy</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants changing or terminating antiplatelet therapy</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>8 months</time_frame>
    <description>Cardiac death, non-coronary death, non-cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
    <description>Cardiac death, non-coronary death, non-cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death, non-coronary death, non-cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>3 years</time_frame>
    <description>Cardiac death, non-coronary death, non-cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>8 months</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>2 years</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>3 years</time_frame>
    <description>Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>8 months</time_frame>
    <description>Target vessel revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Target vessel revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>2 years</time_frame>
    <description>Target vessel revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>3 years</time_frame>
    <description>Target vessel revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>8 months</time_frame>
    <description>As per academic research consortium (ARC) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>As per academic research consortium (ARC) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>2 years</time_frame>
    <description>As per academic research consortium (ARC) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>3 years</time_frame>
    <description>As per academic research consortium (ARC) definition</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>XIENCE Xpedition 2.25 mm stent arm</arm_group_label>
    <description>Patients receiving XIENCE Xpedition 2.25 mm stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE Xpedition 2.25 mm stent</intervention_name>
    <description>Patients receiving XIENCE Xpedition 2.25 mm stent</description>
    <arm_group_label>XIENCE Xpedition 2.25 mm stent arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        General patient population with ischemic heart disease in Japan who are eligible for
        treatment with XIENCE Xpedition 2.25 mm stent will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Patient informed consent is required for registration of this PMS. In cases where
             patient informed consent (or providing some type of information) is required for PMS
             per the participating site policy, the Sponsor will cooperate as needed.

          -  If it is known at the time of index procedure that the patient is not able to return
             for the 8-month follow-up visit for angiogram and for the 1-year clinical follow-up,
             then the patient should not be registered in the PMS.

          -  Patients who are attending or will attend other PMS with invasive medical procedure
             will not be registered.

          -  Patients who are treated by XIENCE Xpedition 2.25mm stent will be registered.

               -  The observations will be compiled on a per-patient basis even if multiple XIENCE
                  Xpedition 2.25mm stents are implanted during the index procedure.

               -  A patient whose side-branch is treated by XIENCE Xpedition 2.25mm stent can be
                  registered. In such a case, main vessel should be treated by XIENCE Xpedition.

               -  The observations will not be compiled on a per-patient basis if a patient is
                  treated by XIENCE Xpedition 2.25mm stent overlapped with other stents for
                  bail-out purpose.

               -  Additional revascularization procedures as a part of adverse event treatment and
                  planned staged procedures will not be considered as another registration, or
                  adverse events.

               -  A patient who is treated, but failed to be implanted by XIENCE Xpedition 2.25mm
                  stent and finally treated by other devices only (No XIENCE Xpedition 2.25mm stent
                  are implanted) must also be registered. In such a case, only the stent
                  information, device deficiency information and reportable adverse events related
                  to the Xpedition stent, if any, are required to be captured. Follow-up of the
                  patient who does not receive any XIENCE Xpedition 2.25mm stent is not required.

          -  A patient may have another lesion(s) that may be treated by larger diameter (â‰¥ 2.5mm)
             stent(s). In such a case, treatment by XIENCE Xpedition is preferable. Lesion(s)
             treated by other than XIENCE Xpedition 2.25mm stent is not considered as the target
             lesion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Kozuma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Teikyo University Hospital, Tokyo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hyogo Prefectural Amagasaki Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>660-0828</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefectural Central Hospital</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Police Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>543-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JCHO Hokkaido Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>062-8618</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima Red Cross Hospital</name>
      <address>
        <city>Tokushima</city>
        <zip>773-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitsui Memorial Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>101-8643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Fujigaoka Hospital</name>
      <address>
        <city>Yokohama</city>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Eluting Stent</keyword>
  <keyword>Coronary Stent</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Stent Thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

